Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

ExeVir emerges with llama-based antibody platform, 1st program for COVID-19

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats.

ExeVir, which debuted Tuesday with a €23 million ($26.9 million) series A financing led by Fund+, will pursue therapies for COVID-19.

Ablynx N.V. was the first company formed by Flanders Institute for Biotechnology (VIB) around camelid antibodies; it launched in 2001 and was acquired 17 years later by Sanofi

Read the full 814 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE